(VIANEWS) – Shares of ImmunoGen (NASDAQ: IMGN) rose by a staggering 31.04% in 21 sessions from $14.37 at 2023-06-02, to $18.83 at 14:58 EST on Tuesday, following the last session’s downward trend. NASDAQ is jumping 0.21% to $13,816.77, after two sequential sessions in a row of gains.
ImmunoGen’s last close was $18.83, 7.2% below its 52-week high of $20.29.
About ImmunoGen
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Earnings Per Share
As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.89.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -111.95%.
Volatility
ImmunoGen’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.33%, a positive 1.40%, and a positive 3.23%.
ImmunoGen’s highest amplitude of average volatility was 0.55% (last week), 2.85% (last month), and 3.23% (last quarter).
More news about ImmunoGen (IMGN).
